Sudha Yarlagadda to Humans
This is a "connection" page, showing publications Sudha Yarlagadda has written about Humans.
Connection Strength
0.066
-
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer. Expert Rev Anticancer Ther. 2025 Jun; 25(6):675-686.
Score: 0.029
-
Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER Trial. JAMA Netw Open. 2025 Dec 01; 8(12):e2549109.
Score: 0.008
-
Clinical Trial Discussion and Participation in a Breast Cancer Cohort by Race and Ethnicity. JAMA Netw Open. 2025 06 02; 8(6):e2515205.
Score: 0.007
-
Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US. JAMA Netw Open. 2025 02 03; 8(2):e2460243.
Score: 0.007
-
Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer. Ann Surg Oncol. 2024 Dec; 31(13):8829-8842.
Score: 0.007
-
Improving the Discharge Process at the VA Palo Alto Through Change Management and Implementation of Project Re-Engineered Discharge. Rehabil Nurs. 2024 May-Jun 01; 49(3):95-100.
Score: 0.007